By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
The most effective method to Distinguish the Best Material Organization in Your Space - 2Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- 3Most loved Occasion Dish: What Makes Your Merry Table?
- 4Finding Ideal Date Spots for Two or three Encounters
- 5Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- New science points to 4 distinct types of autism
- Discovering a true sense of harmony: Contemplation and Care Practices
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- Andrew McCarthy's awe-inspiring image of a skydiver in front of the sun
- You finally got a doctor's appointment. Here's how to get the most out of it
- Wolf Bites Woman in Shocking Attack at Busy Shopping Center
- How do my eyes adjust to the dark and how long does it take?
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
